REG - ValiRx PLC - New Evaluation and Material Transfer Agreement

ValiRxAnnouncement

03/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC1164La&default-theme=true

RNS Number : 1164L  ValiRx PLC  03 June 2025

3 June 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

New Evaluation and Material Transfer Agreement

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to announce
that its majority owned subsidiary, Cytolytix Ltd. ("Cytolytix") and  Omios
Biologics ("Omios"), a California based corporation, have entered into an
Evaluation and Material Transfer agreement to evaluate the ability of
Cytolytix's CLX001 oncolytic peptide technology to enhance activity of Omios's
next-generation oncolytic virus immunotherapies (the "Agreement").

The Agreement focuses on incorporating Cytolytix's Oncolytic Peptide
technology into the Omios next-generation Oncolytic Virus platform and is
expected to take up to 12 months, for a nominal upfront payment. On conclusion
of the evaluation, Omios has an option to enter into an Oncolytic Peptide
License Agreement to continue using Cytolytix technology. This signifies an
exciting new opportunity for ValiRx and Cytolytix to further expand its
portfolio and commercialise its portfolio of innovative cancer therapeutics.

Mark Eccleston, CEO of ValiRx commented "We are pleased to announce this
first Cytolytix commercial evaluation with Omios Bio and we see great synergy
with their virus platform with a built-in biomarker for tumour targeting. We
are very excited to work with Omios on the next generation of oncolytic virus
leveraging Cytolytix's oncolytic peptide technology to enhance activity.
Omios's innovative approach to enhancing their viruses' ability to selectively
target and destroy cancer cells offers great synergy with our oncolytic
peptide technology."

 

Aldo Pourceht, CEO of Omios Biologics commented "Our agreement with Cytolytix
marks a significant strategic advancement for Omios. We look forward to
evaluating how Cytolytix's oncolytic peptides can maximize the therapeutic
impact of our next-generation VACV therapies. This collaboration is perfectly
aligned with our core strategy: to build a leading oncolytic immunotherapy and
tumor-targeted gene delivery platform, and most importantly, to rapidly
advance our transformative cancer treatments into the clinic, for patients
with challenging solid tumors."

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/Ve9mNe

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDDGDLGBGDGUD